Marked improvement in nail psoriasis during treatment with adalimumab

Dermatology

Volumn 219, Issue 4, 2009, Pages 353-356

  Irla, N ^a   Yawalkar, N ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adalimumab; Biologics; Nail psoriasis, treatment

Indexed keywords

ADALIMUMAB; COLECALCIFEROL; STEROID;

ADULT; ARTICLE; CASE REPORT; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MALE; MONOTHERAPY; NAIL DYSTROPHY; NAIL PSORIASIS; PAIN ASSESSMENT; PATIENT COMPLIANCE; PATIENT REFERRAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RELAPSE; REMISSION; RETREATMENT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; MALE; MIDDLE AGED; NAIL DISEASES; PSORIASIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 72449136160     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000252853     Document Type: Article

References (16)

1. Scher RK: Psoriasis of the nail. Dermatol Clin 1985; 3: 387-394.
2. Cassell S, Kavanaugh AF: Therapies for psoriatic nail disease. J Rheumatol 2006; 33: 1452-1456.
3. McGonagle D, Tan AL, Benjamin M: The nail as a musculoskeletal appendage - implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009; 218: 97-102.
4. Rigopoulos D, Gregoriou D, Daniel CR III, et al: Treatment of nail psoriasis with a twocompound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology 2009; 218: 338-341.
5. De Berker D: Management of nail psoriasis. Clin Exp Dermatol 2000; 25: 357-362.
6. Mahrle G, Schulze HJ, Farber L, et al: Lowdose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail and joint involvement. J Am Acad Dermatol 1995; 32: 78-88.
7. Rallis E, Stavropoulou E, Rigopoulos D, et al: Rapid response of nail psoriasis of etanercept. J Rheumatol 2008; 35: 544-545.
8. Rich P, Griffiths CEM, Reich K, et al: Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224-231.
9. Rigopoulos D, Gregoriou S, Stratigos A, et al: Evaluation of the efficacity and safety of infliximab on psoriatic nails: An unblinded, nonrandomized, open-label study. Br J Dermatol 2008; 159: 453-456.
10. Calabrese LH: Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003; 21: 241-248.
11. Menter A, Tyring SK, Gordon K, et al: Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
12. Saurat JH, Stingl G, Dubertret L, et al: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
13. Lamerson C, Stevens G, Sax K: Treatment of nail psoriasis with efalizumab: A preliminary study. Cutis 2008; 82: 217-220.
14. Körver JEM, Langewouters AMG, Van De Kerkhof PCM, et al: Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 1252-1255.
15. Cassetty CT, Alexis AF, Shupack JL, et al: Alefacept in the treatment of psoriatic nail disease: A small case series. J Am Acad Dermatol 2005; 52: 1101-1102.
16. Stensen M, Lockshin M, Doria A, et al: Update on safety during pregnancy of biological agents and some immunosuppressive antirheumatic drugs. Rheumatology 2008; 47: Iii28-iii31.